The new approval is the first for the drug under JNJ leadership. ・The drug is also approved for the treatment of bipolar I ...

Results from the largest and longest study of its kind have found that the drug metformin can help manage weight gain in ...

NDA submission expected in early Q1 2026 for expanded usage of IGALMI® in home setting based on positive data from the ...

Caplyta, the crown jewel of Johnson & Johnson's $14.6 billion buyout of Intra-Cellular Therapies, won the FDA’s blessing to ...

A new combination of pre-existing drugs may have unlocked a new treatment for bipolar depression, a Columbia University study released Wednesday found. The study suggests a way to prolong the effects ...

Just over a year ago, the first new drug for schizophrenia in nearly 50 years was approved. Now, scientists are starting to ...

A new study examining real-world hospital data reveals early indicators of who is most likely to benefit from Cobenfy, the ...

Clinical trials in human beings are in progress on using heart drugs for the treatment of bipolar disorder following its ...

One of the most commonly prescribed antidepressants, sertraline, may begin to relieve some key symptoms of depression and ...

Mr. Rawls received an option to purchase 90,000 shares of LB Pharmaceuticals’ common stock. The option carries a ten-year term and an exercise price per share equal to $14.61, which was the closing ...

Today, BD², or Breakthrough Discoveries for thriving with Bipolar Disorder, announced its third round of Discovery Research grants, totaling nearly $18 million – expanding a comprehensive global ...

Cobenfy, the first new schizophrenia drug in 50 years, offers early insights that could pave the way for more personalized ...